Breaking Finance News

Zacks Investment Research upgraded Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to Hold in a report released today.

Zacks Investment Research has upgraded Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to Hold in a report released on 10/10/2016.

Previously on Friday September 30, 2016, Raymond James released a statement about Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) increased the target price from $0.00 to $16.00. At the time, this indicated a possible upside of 1.23%.

Just yesterday Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) traded 3.91% higher at $6.67. Adaptimmune Therapeutics PLC – ADR’s 50-day moving average is $7.06 and its 200-day moving average is $8.43. The last stock price is down -21.09% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 169,014 shares of ADAP traded hands, up from an average trading volume of 143,965

Recent Performance Chart

Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC – ADR has 52 week low of $6.19 and a 52 week high of $14.78 and has a market capitalization of $0.

Brief Synopsis On Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company's TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.